Q-omics provides the consensus-scored MTND6P21 profile across patient tissues and cancer cell-line models. MTND6P21 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MTND6P21 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, MTND6P21 RNA expression shows 14,880 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where MTND6P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND6P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND6P21 survival associations across molecular data types. MTND6P21 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND6P21 RNA expression–survival associations across cancer types. High MTND6P21 expression shows unfavorable associations in UCEC, KIRP, LUSC and CHOL, but favorable associations in HNSC and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for MTND6P21 RNA expression.
This table summarizes MTND6P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MTND6P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND6P21 shows lower tumor expression in COAD, BRCA, BLCA, STAD and UCEC and higher tumor expression in KICH. The COAD box plot shows higher MTND6P21 RNA expression in normal versus tumor tissue (log2 FC = −0.263, t-test p < 0.001).
This table shows molecular features associated with MTND6P21 in patient tissues and cancer cell lines. In patient samples, MTND6P21 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
